Business Context and Reporting Period
Company: Cara Therapeutics, Inc. (Note: Input metadata referenced "Tvardi Therapeutics," but the filing text identifies the registrant as Cara Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date: May 29, 2019
Event: Announcement of top-line data from the KALM-1 Phase 3 clinical trial for KORSUVA (difelikefalin) injection.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The primary material event is the successful completion of the KALM-1 Phase 3 trial evaluating KORSUVA for hemodialysis patients with moderate-to-severe pruritus. Key efficacy results include:
- Primary Endpoint: 51% of patients receiving KORSUVA achieved a ≥3-point improvement in itch score at week 12, compared to 28% for placebo (p=0.000019).
- Secondary Endpoint (4-point improvement): 39% of KORSUVA patients achieved this threshold versus 18% for placebo (p=0.000032).
- Quality of Life: KORSUVA showed a 43% improvement in Skindex-10 scores and a 35% improvement in 5-D Itch scores compared to placebo.
Outlook, Risks, and Safety Profile
Safety and Tolerability: KORSUVA was generally well-tolerated with a safety profile consistent with earlier trials. The incidence of adverse events (AEs) and serious AEs was similar between KORSUVA and placebo groups.
Common Adverse Events (≥5% incidence):
- Diarrhea (9.5% KORSUVA vs. 3.7% placebo)
- Dizziness (6.9% KORSUVA vs. 1.1% placebo)
- Nasopharyngitis (5.3% KORSUVA vs. 3.2% placebo)
- Vomiting (5.3% KORSUVA vs. 3.2% placebo)
Regulatory Status: The information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the statistical significance and clinical relevance of the p-values reported (p=0.000019 and p=0.000032).
- Review the full safety data in the referenced press release (Exhibit 99.1) and presentation (Exhibit 99.2) for details on serious adverse events.
- Confirm the timeline for the 52-week open-label extension phase mentioned in the trial design.
- Assess the potential impact of these results on the company's regulatory submission strategy for FDA approval.
- Check subsequent filings for any updates on the company's cash position, as this 8-K does not provide financial liquidity data.